Trevi Therapeutics, Inc.
Clinical-stage biopharma developing an oral therapy for chronic cough in IPF and RCC.
TRVI | NDAQ
Overview
Corporate Details
- ISIN(s):
- US89532M1018
- LEI:
- Country:
- United States of America
- Address:
- 195 CHURCH STREET, 6510 NEW HAVEN
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing its investigational therapy, Haduvio™ (oral nalbuphine ER). The company's primary focus is addressing chronic cough in patients with conditions such as idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is a dual-mechanism therapy that acts as a kappa opioid receptor agonist and a mu opioid receptor antagonist, targeting the cough reflex arc both centrally and peripherally. Trevi aims to address a significant unmet medical need, as there are currently no approved therapies in the U.S. for these debilitating conditions. The company has announced positive results from its Phase 2 clinical trials, demonstrating a statistically significant reduction in cough frequency.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Trevi Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Trevi Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Trevi Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
